Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 12/20 | 0.85 |
| ▸ | NOS1 | P29475 | 12/20 | 0.85 |
| ▸ | NOS2 | P35228 | 12/20 | 0.85 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833909 | 0.93 | NOS3 (0.98) | NOS3NOS1NOS2HRH3HTR2A | |
| SCHEMBL5834017 | 0.92 | NOS3 (1.00) | NOS3NOS1NOS2HRH3HTR2A | |
| SCHEMBL7083855 | 0.91 | NOS3 (0.88) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL7126075 | 0.84 | NOS3 (0.79) | NOS3NOS1NOS2HRH3HTR2A | |
| SCHEMBL5834368 | 0.84 | NOS3 (1.00) | NOS3NOS1NOS2 | |
| SCHEMBL5833641 | 0.83 | NOS3 (0.81) | NOS3NOS1NOS2KDM4E | |
| SCHEMBL5833437 | 0.81 | NOS1 (0.78) | NOS3NOS1NOS2HTR2AHTR7 | |
| SCHEMBL5833259 | 0.79 | NOS3 (0.75) | NOS3NOS1NOS2 | |
| SCHEMBL5833767 | 0.79 | NOS3 (0.76) | NOS3NOS1NOS2 | |
| SCHEMBL7409113 | 0.79 | NOS3 (0.75) | NOS3NOS1NOS2HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155000-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | claimed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | claimed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | claimed |
| EP-1155000-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6372768-B2 | NERVOUS SYSTEM DISORDERS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| EP-1155000-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | disclosed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| WO-2000050400-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | CBR1, CBR3, NOS2 | NOS3 4/4885NOS1 5/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.